Here are four notes:
1. The clinical trial compared the 24-month outcomes of Amedica’s porous silicon nitride product versus bone autograft for single-level cervical fusion.
2. The trial’s results showed the two had comparable outcomes.
3. The FDA will make its final decision regarding the product’s clearance in 60 days.
4. Once approved, Amedica will begin manufacturing and selling the CASCADE product.
More articles on devices:
Global spine surgery robots market to hit $2.77B by 2022 — 4 points
NuVasive stock reaches new 52-week high: 3 points
Asia Pacific spine surgery devices market to reach $2.2B by 2019 — 4 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
